Statement: the primary trial and the secondary trial recorded the exact same number of cases of nausea.
Primary_evidence: Adverse Events 1:   Total: 9/23 (39.13%)   Anemia  1/23 (4.35%)   Diarrhea  1/23 (4.35%)   Nausea  1/23 (4.35%)   Fracture  1/23 (4.35%)   ALT  1/23 (4.35%)   AST  1/23 (4.35%)   INR  1/23 (4.35%)   PTT  1/23 (4.35%)   Glucose, high  1/23 (4.35%)   Limb Pain  1/23 (4.35%)   Ataxia  2/23 (8.70%)   Neurology - Other  1/23 (4.35%)   Seizure  1/23 (4.35%)   Syncope  1/23 (4.35%)   Confusion  1/23 (4.35%)
Secondary_evidence: Adverse Events 1:   Total: 14/52 (26.92%)   Febrile neutropenia * 1/52 (1.92%)   Tachycardia * 1/52 (1.92%)   Atrial fibrillation * 0/52 (0.00%)   Duodenal ulcer * 1/52 (1.92%)   Gastric ulcer * 1/52 (1.92%)   Nausea * 1/52 (1.92%)   Abdominal pain * 0/52 (0.00%)   Asthenia * 1/52 (1.92%)   Disease progression * 1/52 (1.92%)   Mucosal inflammation * 1/52 (1.92%)   Appendicitis * 1/52 (1.92%) Adverse Events 2:   Total: 4/20 (20.00%)   Febrile neutropenia * 0/20 (0.00%)   Tachycardia * 0/20 (0.00%)   Atrial fibrillation * 1/20 (5.00%)   Duodenal ulcer * 0/20 (0.00%)   Gastric ulcer * 0/20 (0.00%)   Nausea * 0/20 (0.00%)   Abdominal pain * 1/20 (5.00%)   Asthenia * 0/20 (0.00%)   Disease progression * 0/20 (0.00%)   Mucosal inflammation * 0/20 (0.00%)   Appendicitis * 0/20 (0.00%)